Washington, D.C. 20549






Current Report

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): January 30, 2013



Corcept Therapeutics Incorporated

(Exact name of registrant as specified in its charter)




Delaware   000-50679   77-0487658

(State or other jurisdiction

of incorporation)



File Number)

  (I.R.S. Employer
Identification Number)

149 Commonwealth Drive

Menlo Park, CA 94025

(Address of principal executive offices, with zip code)

(650) 327-3270

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former, address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Increase in Salaries for Named Executive Officers

(e) On January 30, 2013, our Board of Directors, or our Board, following the recommendation of the Compensation Committee of our Board, approved an increase in the annual base salary of each of the following named executive officers, with such increase to be effective on February 1, 2013, in the following amounts:


Named Executive Officer

   2012 Annual Base Salary      New Annual Base Salary  

Joseph K. Belanoff (principal executive officer)

   $ 481,097       $ 530,000   

G. Charles Robb

   $ 309,000       $ 340,000   

Steven Lo

   $ 318,270       $ 350,000   




Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



/s/ G. Charles Robb

  Name: G. Charles Robb
  Title:   Chief Financial Officer

Date: February 5, 2012